FY2029 Earnings Forecast for APRE Issued By Wedbush

Aprea Therapeutics, Inc. (NASDAQ:APRE) – Equities researchers at Wedbush issued their FY2029 earnings estimates for Aprea Therapeutics in a note issued to investors on Tuesday, March 25th. Wedbush analyst R. Driscoll anticipates that the company will earn $2.19 per share for the year. Wedbush currently has a “Outperform” rating and a $11.00 target price on the stock. The consensus estimate for Aprea Therapeutics’ current full-year earnings is ($2.55) per share.

Aprea Therapeutics (NASDAQ:APRE) last announced its quarterly earnings data on Tuesday, March 25th. The company reported ($0.49) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.69) by $0.20. The business had revenue of $0.21 million during the quarter, compared to the consensus estimate of $0.15 million. Aprea Therapeutics had a negative net margin of 1,029.50% and a negative return on equity of 57.86%.

Separately, HC Wainwright reiterated a “buy” rating and set a $20.00 target price on shares of Aprea Therapeutics in a research report on Wednesday, January 15th.

Aprea Therapeutics Stock Performance

Shares of APRE stock opened at $2.24 on Thursday. The stock has a 50 day moving average price of $3.10 and a 200 day moving average price of $3.25. The firm has a market capitalization of $12.17 million, a P/E ratio of -0.80 and a beta of 0.82. Aprea Therapeutics has a 52-week low of $2.15 and a 52-week high of $6.80.

Hedge Funds Weigh In On Aprea Therapeutics

A number of institutional investors have recently modified their holdings of the stock. Landscape Capital Management L.L.C. purchased a new stake in shares of Aprea Therapeutics in the fourth quarter valued at approximately $116,000. LPL Financial LLC bought a new stake in Aprea Therapeutics during the 4th quarter valued at $53,000. BNP Paribas Financial Markets purchased a new stake in shares of Aprea Therapeutics in the 4th quarter worth $43,000. Finally, Stonepine Capital Management LLC grew its position in shares of Aprea Therapeutics by 8.8% during the 4th quarter. Stonepine Capital Management LLC now owns 149,221 shares of the company’s stock worth $491,000 after buying an additional 12,047 shares in the last quarter. 34.19% of the stock is owned by hedge funds and other institutional investors.

Aprea Therapeutics Company Profile

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.